IL297149A - Compounds and Methods for Splicing Regulation - Google Patents
Compounds and Methods for Splicing RegulationInfo
- Publication number
- IL297149A IL297149A IL297149A IL29714922A IL297149A IL 297149 A IL297149 A IL 297149A IL 297149 A IL297149 A IL 297149A IL 29714922 A IL29714922 A IL 29714922A IL 297149 A IL297149 A IL 297149A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- heterocyclyl
- heteroaryl
- aryl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Replacement Of Web Rolls (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007327P | 2020-04-08 | 2020-04-08 | |
| US202063043920P | 2020-06-25 | 2020-06-25 | |
| US202063072873P | 2020-08-31 | 2020-08-31 | |
| US202063126493P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/026477 WO2021207550A1 (en) | 2020-04-08 | 2021-04-08 | Compounds and methods for modulating splicing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297149A true IL297149A (en) | 2022-12-01 |
Family
ID=75747105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297149A IL297149A (en) | 2020-04-08 | 2021-04-08 | Compounds and Methods for Splicing Regulation |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240287097A1 (enExample) |
| EP (2) | EP4132936A1 (enExample) |
| JP (2) | JP7797407B2 (enExample) |
| KR (2) | KR20230004575A (enExample) |
| CN (2) | CN116096725A (enExample) |
| AU (2) | AU2021251220A1 (enExample) |
| BR (2) | BR112022020418A2 (enExample) |
| CA (2) | CA3175205A1 (enExample) |
| CL (1) | CL2022002779A1 (enExample) |
| CO (1) | CO2022015926A2 (enExample) |
| CR (1) | CR20220567A (enExample) |
| IL (1) | IL297149A (enExample) |
| MX (2) | MX2022012677A (enExample) |
| WO (2) | WO2021207550A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| IL297963A (en) | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Antagonists of the adenosine a2a receptor |
| WO2021231571A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| EP4308577B1 (en) * | 2021-03-17 | 2024-12-25 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
| CR20230437A (es) * | 2021-03-17 | 2023-10-16 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona |
| EP4308572B1 (en) * | 2021-03-17 | 2025-04-23 | F. Hoffmann-La Roche AG | New thienopyrimidinone derivatives |
| TW202330552A (zh) * | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| JP2024541481A (ja) * | 2021-11-24 | 2024-11-08 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
| CN115112899B (zh) * | 2022-06-15 | 2024-08-16 | 四川大学华西医院 | 检测羧肽酶a4的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途 |
| CN121653249B (zh) * | 2026-02-09 | 2026-05-26 | 中国医学科学院医学生物学研究所 | Dnal1基因作为靶点在筛选防治寨卡病毒或2型登革病毒感染药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB242502A (en) * | 1925-03-10 | 1925-11-12 | Hoe & Co R | Improvements in stapling and folding mechanism |
| JPS57142989A (en) * | 1981-02-27 | 1982-09-03 | Dai Ichi Seiyaku Co Ltd | Thiazolopyrimidine derivative |
| JPS58177997A (ja) * | 1982-04-12 | 1983-10-18 | Dai Ichi Seiyaku Co Ltd | チアジアゾロピリミジノン誘導体 |
| ES2016293B3 (es) * | 1986-03-19 | 1990-11-01 | Kumiai Chemical Industry Co | Fungicida agricola-horticola. |
| TW449600B (en) * | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| US6153614A (en) | 1998-07-16 | 2000-11-28 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
| AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
| US20060194871A1 (en) | 2003-04-11 | 2006-08-31 | Barvian Kevin K | Heterocyclic mchr1 antagoists |
| WO2005047293A1 (en) * | 2003-11-07 | 2005-05-26 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| US7745447B2 (en) * | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| WO2008057601A2 (en) * | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| EP2593106A4 (en) | 2010-07-16 | 2014-01-01 | Univ Rockefeller | ORGANIC CONNECTIONS |
| JP2014519519A (ja) | 2011-06-15 | 2014-08-14 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物 |
| US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2013109632A2 (en) | 2012-01-16 | 2013-07-25 | The Rockefeller University | Organic compounds |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| TWI693227B (zh) * | 2014-04-23 | 2020-05-11 | 日商田邊三菱製藥股份有限公司 | 新穎二環性或三環性雜環化合物 |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| WO2015185531A1 (de) | 2014-06-05 | 2015-12-10 | Bayer Cropscience Aktiengesellschaft | Bicyclische verbindungen als schädlingsbekämpfungsmittel |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN106279211B (zh) | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| JP6791717B2 (ja) * | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AR106472A1 (es) * | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| SG11201902588PA (en) * | 2016-09-23 | 2019-05-30 | Bayer Ag | N3-Cyclically Substituted Thienouracils And Use Thereof |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| KR102736865B1 (ko) * | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
| US10584133B2 (en) | 2018-03-30 | 2020-03-10 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| CR20230437A (es) * | 2021-03-17 | 2023-10-16 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona |
| EP4308577B1 (en) * | 2021-03-17 | 2024-12-25 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
-
2021
- 2021-04-08 MX MX2022012677A patent/MX2022012677A/es unknown
- 2021-04-08 CN CN202180040958.1A patent/CN116096725A/zh active Pending
- 2021-04-08 IL IL297149A patent/IL297149A/en unknown
- 2021-04-08 MX MX2022012676A patent/MX2022012676A/es unknown
- 2021-04-08 EP EP21722693.5A patent/EP4132936A1/en active Pending
- 2021-04-08 JP JP2022561468A patent/JP7797407B2/ja active Active
- 2021-04-08 CA CA3175205A patent/CA3175205A1/en active Pending
- 2021-04-08 EP EP21722687.7A patent/EP4132935A1/en active Pending
- 2021-04-08 US US17/917,868 patent/US20240287097A1/en active Pending
- 2021-04-08 KR KR1020227039049A patent/KR20230004575A/ko active Pending
- 2021-04-08 AU AU2021251220A patent/AU2021251220A1/en active Pending
- 2021-04-08 AU AU2021253571A patent/AU2021253571A1/en active Pending
- 2021-04-08 KR KR1020227039044A patent/KR20230005210A/ko active Pending
- 2021-04-08 BR BR112022020418A patent/BR112022020418A2/pt active Search and Examination
- 2021-04-08 JP JP2022561469A patent/JP7882782B2/ja active Active
- 2021-04-08 CR CR20220567A patent/CR20220567A/es unknown
- 2021-04-08 WO PCT/US2021/026477 patent/WO2021207550A1/en not_active Ceased
- 2021-04-08 WO PCT/US2021/026435 patent/WO2021207530A1/en not_active Ceased
- 2021-04-08 BR BR112022020337A patent/BR112022020337A2/pt unknown
- 2021-04-08 US US17/917,842 patent/US20240279239A1/en active Pending
- 2021-04-08 CN CN202180040768.XA patent/CN116134036A/zh active Pending
- 2021-04-08 CA CA3175193A patent/CA3175193A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002779A patent/CL2022002779A1/es unknown
- 2022-11-04 CO CONC2022/0015926A patent/CO2022015926A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132936A1 (en) | 2023-02-15 |
| BR112022020337A2 (pt) | 2022-12-13 |
| US20240279239A1 (en) | 2024-08-22 |
| WO2021207530A8 (en) | 2021-12-02 |
| KR20230005210A (ko) | 2023-01-09 |
| EP4132935A1 (en) | 2023-02-15 |
| BR112022020418A2 (pt) | 2023-05-02 |
| MX2022012676A (es) | 2023-01-11 |
| CL2022002779A1 (es) | 2023-04-28 |
| US20240287097A1 (en) | 2024-08-29 |
| CA3175193A1 (en) | 2021-10-14 |
| CN116096725A (zh) | 2023-05-09 |
| AU2021251220A1 (en) | 2022-11-03 |
| WO2021207550A1 (en) | 2021-10-14 |
| JP7882782B2 (ja) | 2026-06-30 |
| AU2021253571A1 (en) | 2022-11-10 |
| WO2021207530A1 (en) | 2021-10-14 |
| JP2023520924A (ja) | 2023-05-22 |
| MX2022012677A (es) | 2023-01-11 |
| CO2022015926A2 (es) | 2022-11-29 |
| CR20220567A (es) | 2023-01-13 |
| JP2023520925A (ja) | 2023-05-22 |
| CA3175205A1 (en) | 2021-10-14 |
| CN116134036A (zh) | 2023-05-16 |
| JP7797407B2 (ja) | 2026-01-13 |
| KR20230004575A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797407B2 (ja) | スプライシングを調節するための化合物及び方法 | |
| AU2021228284A1 (en) | Compounds and methods for modulating splicing | |
| IL297137A (en) | Splicing Modulation Compounds and Methods | |
| WO2021174170A9 (en) | Pyridazine derivatives for modulating nucleic acid splicing | |
| EP4416156A1 (en) | Compounds and methods for modulating nucleic acid splicing | |
| IL299543A (en) | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases | |
| IL311132A (en) | Splicing Modulation Compounds and Methods | |
| WO2024259017A1 (en) | Compounds and methods for modulating splicing | |
| WO2024259015A1 (en) | Compounds and methods for modulating splicing | |
| EP4395889A1 (en) | Compounds and methods for modulating splicing |